openPR Logo
Press release

Pompe Disease Treatment Market Analysis with Future Prospects to 2026 | Amicus Therapeutics, Inc., Takeda Pharmaceutical Company, Sanofi,, Valerion Therapeutics

11-08-2019 08:18 AM CET | Health & Medicine

Press release from: Data Bridge Market Research

Pompe Disease Treatment Market

Pompe Disease Treatment Market

Pompe Disease Treatment Market 2019, A recent report published by Data Bridge Market Research provides a unique guidance in thoughtful details regarding the development factors, used a top-down and bottom-up approach to keep it error-free and accurate. The researchers have used primary and secondary methodologies to collect data and its analysis.

The POMPE DISEASE TREATMENT MARKET data covered in the report will give the reader a comprehensive understanding of the market as well as the major players in terms of production and the regions with high demand and supply.

This market is rising gradually with a substantial CAGR of 8.81% in the forecast period of 2019-2026. Few of the leading organizations’ names are listed here- Amicus Therapeutics, Inc., Takeda Pharmaceutical Company, Sanofi,, Valerion Therapeutics, Sangamo Therapeutics, Oxyrane, EpiVax, Inc., Alexion Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc., Audentes Therapeutics, Spark Therapeutics, Inc., Pfizer Inc., BioMarin, ABIOMED, Sarepta Therapeutics,. Biogen, Genentech, Inc., among others.

Request for sample copy or PDF with (Market Segments, Forecast, Key player's and TOC) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pompe-disease-treatment-market

Let’s know why the report is worth considering-

Pompe disease is a genetic disorder that is caused by the buildup of a complex sugar called glycogen in cells and tissues. This accumulation of glycogen causes impairment in organs and tissues. This disease majorly causes muscle wasting, muscle weakness and other complications such as cardiac problems and respiratory disorders. GAA gene is responsible for breakdown of glycogen in the body. In Pompe disease, mutation occurs in GAA gene that results in accumulation of glycogen in tissues and organs.

The incidence rate of Pompe disease is approximately 1 in 40,000 births in the United States. Pompe disease occurs in males and females in same number. However, the incidence of this disease varies in different ethnic groups.

Performs Competitive Analysis: The Pompe Disease Treatment report incorporates the detailed analysis of the leading organizations and their thought process and what are the methodologies they are adopting to maintain their brand image in this market. The report aides the new bees to understand the level of competition that they need to fight for to strengthen their roots in this competitive market.

Highlights following MARKET DRIVERS AND RESTRAINT:

Advancement in the gene therapy and enzyme replacement therapies also acts as a market driver
Rising healthcare infrastructure for Pompe disease drugs will expand the market size
Rising prevalence rate of people suffering from Pompe disease is expected to drive the market growth in the forecast period
Limited patient pool and heterogeneity of the disease in different regions hampers the market growth
High cost associated with the therapy will also restrict the market growth

Purchase this Report with 30% Discount at -https://databridgemarketresearch.com/request-a-discount/global-pompe-disease-treatment-market

Conducts Overall POMPE DISEASE TREATMENT Market Segmentation: This knowledgeable market research report offers lucrative opportunities by breaking down complex market data into segments on the basis of –

By Type (Classic Infantile-Onset Pompe Disease, Non-Classic Infantile-Onset Pompe Disease, Late-Onset Pompe Disease),

Therapy Type (Medication, Enzyme Replacement Therapy, Physiotherapy, Others),

Route of Administration (Oral, Injectable, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others),

Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)

The POMPE DISEASE TREATMENT report covers market shares for global, Europe, North America, Asia Pacific and South America. The analysis of this report has been used to examine various segments that are relied upon to witness the quickest development based on the estimated forecast frame.

Key Developments in the Market:

In February 2019 Amicus Therapeutics, Inc. received Breakthrough Therapy Designation from the U. S. FDA for AT-GAA a novel treatment that consist ATB200, a recombinant human acid alpha-glucosidase (rhGAA) enzyme used for the treatment of patients with Pompe disease. This grant will expedite the development and review of AT-GAA for pompe disease

In March 2017, Valerion Therapeutics developed VAL-1221, a combination fusion protein synthesized by antibody delivery technology and recombinant human acid alpha-glucosidase (rhGAA) for treatment of patients with Pompe disease. This therapy is advanced as it has the ability to act on glycogen present in cytoplasm of late-onset pompe disease patients. This development will bring an effective novel therapy for Pompe disease and enhance the market of the company

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Hair Tie market

Chapter 2: Evaluating the leading manufacturers of the Pompe Disease Treatment market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting Pompe Disease Treatment market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Read Complete Details with TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-pompe-disease-treatment-market                   

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

UK: +44 208 089 1725   

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pompe Disease Treatment Market Analysis with Future Prospects to 2026 | Amicus Therapeutics, Inc., Takeda Pharmaceutical Company, Sanofi,, Valerion Therapeutics here

News-ID: 1863693 • Views: 1876

More Releases from Data Bridge Market Research

Uninterruptible Power Supply Market Country Level Analysis: TOSHIBA CORPORATION, …
This comprehensive Global Uninterruptible Power Supply (UPS) Market report underlines the primary and secondary drivers, market share, possible sales volume, leading segments, and geographical analysis. The report presents relevant data about the different dangers and difficulties looked by various stakeholders. With the proper utilization of established and advanced tools such as SWOT analysis and Porter's Five Forces Analysis, this market report has been structured. The Uninterruptible Power Supply (UPS) Market
Train Signalling System Industry Analysis and Insights: Mipro Oy, Kyosan Electri …
The "Global Train Signalling System Market" report has been produced with the systematic gathering and analysis of information about individuals or organizations conducted through social and opinion research. With the studies, insights, and analysis mentioned in the report, you get a comprehensible idea about the marketplace with which you can take business decisions quickly and easily. The worldwide Train Signalling System Market advertise report comprises of all the organization profiles
Smart Building Market at a CAGR of 34.1% by Top Players | TYCO International, Co …
Global Smart Building Market accounted for USD 5.89 billion in 2017 and is projected to grow at a CAGR of 34.1% the forecast to 2026. Smart Building Market report presents the company profiles of the key vendors and comprehensively analyzes their core competencies to increase an adaptive perspective on the competitive scene and helps the readers to plan the strategies accordingly-: ABB Group, Siemens AG, Schneider Electric, Cisco Systems, Inc., International
Retinitis pigmentosa Treatment Market to Witness Huge Growth by 2026: Astellas P …
Retinitis pigmentosa Treatment Market In-depth Analysis 2019-2026 This Market report is an exceptional report that makes it possible to the industry to take strategic decisions and achieve growth objectives. The analysis of this report has been used to examine various segments that are relied upon to witness the quickest development based on the estimated forecast frame. Worldwide Retinitis pigmentosa Treatment Industry 2019 Market Research Report is spread crosswise over 129 pages and

All 5 Releases


More Releases for Pompe

Pompe Disease Therapeutic Market - Attractive Growth Opportunities 2017 - 2025
Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for
Pompe Disease Market Growth Analysis up to 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market Intelligence with Competitive Landscape 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market Size – Industry Share Report 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Global Pompe Disease Industry Growth and Analysis 2016 – 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market : Size, Status and Forecast 2016 - 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies